An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression

INTRODUCTION: IgA nephropathy (IgAN) is the most common glomerulonephritis with high risk of progression to end-stage renal disease in patients with proteinuria >1 g/24 hours. There are no known effective treatments in patients with IgAN. METHODS: We conducted a prospective open-label pilot study...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Kidney Int Rep
Glavni autori: Zand, Ladan, Canetta, Pietro, Lafayette, Richard, Aslam, Nabeel, Jan, Novak, Sethi, Sanjeev, Fervenza, Fernando C.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2019
Teme:
Clinical Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6943772/
https://ncbi.nlm.nih.gov/pubmed/31922061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2019.10.007
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items